Morning or afternoon? new study tests best time for bladder cancer treatment

NCT ID NCT07346053

First seen Jan 17, 2026 · Last updated May 12, 2026 · Updated 16 times

Summary

This study looks at whether giving standard advanced bladder cancer drugs (enfortumab vedotin and pembrolizumab) in the morning or afternoon changes how well they work or how many side effects they cause. About 224 adults with advanced bladder cancer will be randomly assigned to receive their treatment either before 11:30 a.m. or after 1:30 p.m. The goal is to see if timing based on the body's natural daily rhythms can improve outcomes and reduce side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BC Cancer - Abbotsford

    Abbotsford British Columbia, British Columbia, V2S 0C2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)

    Kelowna, British Columbia, V1Y 5L3, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • BC Cancer - Surrey

    Surrey, British Columbia, V3V 1Z2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • BC Cancer - Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • BC Cancer - Victoria

    Victoria, British Columbia, V8R 6V5, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.